Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Up 8.6% in January

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 4,820,000 shares, an increase of 8.6% from the December 31st total of 4,440,000 shares. Currently, 19.6% of the shares of the company are sold short. Based on an average trading volume of 400,900 shares, the short-interest ratio is currently 12.0 days.

Institutional Trading of Arcturus Therapeutics

Several institutional investors have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Arcturus Therapeutics in the 3rd quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares during the period. SG Americas Securities LLC purchased a new position in shares of Arcturus Therapeutics in the third quarter worth approximately $191,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 846 shares in the last quarter. Finally, Spire Wealth Management lifted its position in Arcturus Therapeutics by 393.3% during the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 10,746 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on ARCT. BTIG Research initiated coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Buy” and an average target price of $61.60.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT traded down $1.30 during midday trading on Monday, reaching $15.67. 245,578 shares of the stock traded hands, compared to its average volume of 399,554. The stock has a market capitalization of $424.42 million, a P/E ratio of -7.08 and a beta of 2.62. Arcturus Therapeutics has a 12 month low of $14.30 and a 12 month high of $45.00. The company has a fifty day moving average of $17.27 and a 200 day moving average of $19.41.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter in the prior year, the business earned ($0.61) EPS. On average, analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.